PolyProx Therapeutics was incorporated in November 2018 and in March 2019 completed its Seed Financing, raising £3.4m from Cambridge Innovation Capital plc, RT Capital and Cambridge Enterprise.
Cambridge Innovation Capital (CIC) is a venture capital investor in IP-rich technology and life science businesses in the Cambridge ecosystem. CIC is committed to building leading businesses from brilliant technologies. It combines a unique relationship with the University of Cambridge with deep financial and industry links to support these businesses as they seek to fulfil their potential and to change the world of tomorrow.
Cambridge Enterprise Limited is a wholly owned subsidiary of the University of Cambridge and is responsible for the commercialisation of University intellectual property. It provides access to early stage capital through the Cambridge Enterprise Seed Funds, University of Cambridge Enterprise Funds and Cambridge Enterprise Venture Partners, and offers business planning, mentoring and related programmes. Activities include management and licensing of intellectual property and patents, proof of concept funding and support for University staff and research groups wishing to provide expert advice or facilities to public and private sector organisations.
RT Capital is a fund managed by RT Partners, a boutique investment firm focused on UK IP-rich technology, with a particular emphasis on bio-tech and genomics. It invests in seed, Series A/B, and growth stage UK technology companies.
Dr Michael Anstey is a Partner at CIC currently managing the investments in Bicycle Therapeutics, Congenica, PredictImmune, Start Codon and Storm Therapeutics. Before joining CIC he was a Principal in the Healthcare Practice area at The Boston Consulting Group (BCG) and was also co-founder and COO of an early stage biotech company focusing on small molecule drugs targeting protein-protein interactions implicated in disease.
As an Investment manager in the Life Sciences team, Christine has a focus on drug discovery with a broad portfolio of technologies, including University of Cambridge spin-outs Carrick, STORM, Z-factor, PhoreMost, Qkine and PolyProx. Previously, Christine worked in the Life Sciences Tech Transfer team managing licensing of University IP, including licences to Cambridge spin-outs. Christine has an MA and DPhil in chemistry from the University of Oxford.
Alex has experience investing in early to late-stage Venture Capital and has led investments into synthetic biology, genomics and data-focussed drug discovery. Prior to RT, Alex founded, invested in, and has advised several businesses in the tech and biotech sector. He is trained as an IP and Corporate Finance lawyer and holds an LL.B (hons) degree in English Law from University College London.